DSS, Inc. Names Jason Grady as Interim Chief Executive Officer
DSS, Inc. (NYSE American: DSS) has appointed Jason Grady as Interim CEO, effective August 23, 2024. Grady, previously COO, succeeds Frank D. Heuszel, who is transitioning to a leadership role at Impact Biomedical, a former DSS subsidiary. With over 25 years of executive experience, Grady has held key positions within DSS, including CEO of DSS Biohealth Holdings and President of Premier Packaging
Grady aims to lead DSS into its next growth phase, focusing on operational efficiency, revenue generation, and reducing cash burn. He acknowledges past challenges and is committed to enhancing shareholder value. This leadership change marks a pivotal moment for DSS as it navigates the evolving business landscape and strives to turn challenges into opportunities.
DSS, Inc. (NYSE American: DSS) ha nominato Jason Grady come CEO ad interim, con effetto dal 23 agosto 2024. Grady, precedentemente COO, succede a Frank D. Heuszel, che sta passando a un ruolo di leadership in Impact Biomedical, un'ex filiale di DSS. Con oltre 25 anni di esperienza esecutiva, Grady ha ricoperto posizioni chiave all'interno di DSS, tra cui CEO di DSS Biohealth Holdings e Presidente di Premier Packaging.
Grady mira a guidare DSS nella sua prossima fase di crescita, concentrandosi su efficienza operativa, generazione di entrate e riduzione dell’uso di liquidità. Riconosce le sfide passate ed è impegnato a migliorare il valore per gli azionisti. Questo cambiamento di leadership segna un momento cruciale per DSS mentre affronta il panorama aziendale in evoluzione e si sforza di trasformare le sfide in opportunità.
DSS, Inc. (NYSE American: DSS) ha nombrado a Jason Grady como CEO interino, efectivo a partir del 23 de agosto de 2024. Grady, previamente COO, sucede a Frank D. Heuszel, quien está en transición a un papel de liderazgo en Impact Biomedical, una ex filial de DSS. Con más de 25 años de experiencia ejecutiva, Grady ha ocupado puestos clave dentro de DSS, incluyendo CEO de DSS Biohealth Holdings y Presidente de Premier Packaging.
Grady tiene como objetivo guiar a DSS hacia su próxima fase de crecimiento, centrándose en la eficiencia operativa, generación de ingresos y reducción del consumo de efectivo. Reconoce los desafíos pasados y está comprometido a mejorar el valor para los accionistas. Este cambio de liderazgo marca un momento crucial para DSS mientras navega por el panorama empresarial en evolución y se esfuerza por convertir los desafíos en oportunidades.
DSS, Inc. (NYSE American: DSS)는 제이슨 그래디를 2024년 8월 23일부로 임시 CEO로 임명했습니다. 이전 COO인 그래디는 DSS의 전 자회사인 임팩트 바이오메딕의 리더십 역할로 전환하는 프랭크 D. 호이젤을 계승합니다. 25년 이상의 경영 경험을 가진 그래디는 DSS 내에서 DSS 바이오헬스 홀딩스의 CEO 및 프리미어 포장사의 회장을 포함한 주요 직책을 역임했습니다.
그래디는 DSS의 다음 성장 단계로 나아가기 위해 운영 효율성, 수익 창출, 현금 소모 감소에 집중할 계획입니다. 그는 과거의 도전을 인식하고 주주 가치를 높이기 위해 노력할 것입니다. 이 리더십 변화는 DSS에게 진화하는 비즈니스 환경을 탐색하고 도전을 기회로 바꾸기 위해 힘쓰는 중요한 순간을 의미합니다.
DSS, Inc. (NYSE American: DSS) a nommé Jason Grady comme PDG par intérim, à compter du 23 août 2024. Grady, précédemment COO, succède à Frank D. Heuszel, qui passe à un rôle de leadership chez Impact Biomedical, une ancienne filiale de DSS. Fort de plus de 25 ans d'expérience dans des postes de direction, Grady a occupé des postes clés au sein de DSS, notamment celui de PDG de DSS Biohealth Holdings et de Président de Premier Packaging.
Grady a pour objectif de guider DSS vers sa prochaine phase de croissance, en se concentrant sur l'efficacité opérationnelle, la génération de revenus et la réduction des dépenses en liquidités. Il reconnaît les défis du passé et s'engage à améliorer la valeur pour les actionnaires. Ce changement de leadership marque un moment charnière pour DSS alors qu'elle navigue dans un paysage commercial en évolution et s'efforce de transformer les défis en opportunités.
DSS, Inc. (NYSE American: DSS) hat Jason Grady als vorläufigen CEO bestellt, der am 23. August 2024 in Kraft tritt. Grady, zuvor COO, folgt auf Frank D. Heuszel, der in eine Führungsrolle bei Impact Biomedical wechselt, einer ehemaligen Tochtergesellschaft von DSS. Mit über 25 Jahren Führungserfahrung hat Grady Schlüsselpositionen innerhalb von DSS innegehabt, darunter CEO von DSS Biohealth Holdings und Präsident von Premier Packaging.
Grady beabsichtigt, DSS in die nächste Wachstumsphase zu führen, indem er sich auf operative Effizienz, Einnahmengenerierung und Reduzierung des Geldverbrauchs konzentriert. Er erkennt die Herausforderungen der Vergangenheit an und engagiert sich für die Steigerung des Shareholder-Values. Dieser Führungswechsel markiert einen entscheidenden Moment für DSS, während es sich durch die sich verändernde Geschäftswelt navigiert und bestrebt ist, Herausforderungen in Chancen zu verwandeln.
- Appointment of experienced executive Jason Grady as Interim CEO
- Focus on operational efficiency and revenue generation
- Commitment to reducing cash burn and eliminating unnecessary waste
- Strategic positioning for growth and expansion across diverse verticals
- Acknowledgment of past challenges faced by the company
- Potential disruption due to leadership transition
- Interim nature of the CEO appointment, indicating potential uncertainty
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) has announced the appointment of Jason Grady as its Interim CEO, effective August 23, 2024. Grady, who previously served as Chief Operating Officer of DSS, Inc., brings over 25 years of extensive experience in executive leadership, business development, restructuring, and operations management across a variety of industries. He will succeed Frank D. Heuszel, who is exiting the company to transition to a leadership role within one of its former subsidiaries.
Throughout his career, Mr. Grady has held pivotal positions within DSS, including CEO and Director of DSS Biohealth Holdings, President of Premier Packaging Corporation, President and COO of DSS Financial Management, and Chief Business Officer of Impact Biomedical, among others.
Mr. Grady's leadership has been instrumental in DSS's strategic evolution and expansion, achieving significant milestones and driving growth across diverse verticals, including Consumer Goods, MedTech, Fintech, Packaging Solutions, Investment Management, and BioHealth. His exceptional track record spans strategic roles in leading companies, where he has advanced go-to-market strategies, executed high-impact mergers and acquisitions, and spearheaded cutting-edge digital transformations. Jason’s expertise uniquely positions him to deliver strategic insights and foster industry-leading growth across DSS’s current and future market sectors.
Mr. Grady acknowledges that the company has faced challenges along the way. "I am deeply honored to lead DSS, Inc. as Interim CEO and guide the company into its next phase of growth and expansion," said Mr. Grady. "As I step into this role, I look forward to working closely with the board, executing its vision, and driving DSS towards a future marked by operational efficiency and revenue generation. By eliminating unnecessary waste, reducing cash burn, and exploring new areas of business, we are committed to building on our robust foundation and confronting challenges with renewed determination. The path ahead is demanding, yet we are well-positioned to adapt, advance, and ultimately enhance shareholder value."
Frank D. Heuszel, outgoing CEO of DSS, Inc., will transition to a leadership role at Impact Biomedical, a long-term investment of DSS focused on discovering, confirming, and patenting unique science and technologies in human healthcare and wellness.
Frank D. Heuszel expressed his enthusiasm for his new role at Impact Biomedical, stating, "I am excited to embark on this new journey with Impact Biomedical, leveraging our strengths to drive impactful advancements in human healthcare and wellness. I wholeheartedly support Jason's transition and am confident in his ability to lead DSS into a prosperous future."
Mr. Grady also expressed his personal gratitude to Mr. Heuszel, stating, "I want to personally thank Frank for his guidance and leadership during his tenure as CEO. His contributions have been invaluable, and I look forward to continuing our collaboration as we both embark on new and exciting chapters."
This strategic leadership transition marks a pivotal moment for DSS, Inc., positioning the company for continued growth, renewed momentum, and sustained shareholder value under Mr. Grady's interim leadership. The path forward will be one of rigorous assessment, adaptability, and strategic execution as the company navigates the evolving business landscape and strives to turn challenges into opportunities.
About DSS, Inc.
DSS is a multinational company operating businesses within four diversified market sectors: Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, Alternative Trading, Digital Transformation, Secure Living, and Alternative Energy. DSS strategically acquires and develops assets to increase shareholder value through periodic IPO spinoffs. Since 2019, under the guidance of new leadership, DSS has built the necessary foundation for achievable growth through the formation of a diversified portfolio of companies positioned to drive profitability in multiple high-growth sectors.
For more information on DSS visit https://www.dssworld.com
Safe Harbor Disclosure
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company's intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in our SEC filings, including, without limitation, our reports on Forms 8-K, 10-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations, and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.
Contact:
DSS Inc. Investor Relations
IR@dssworld.com
+1 (585) 565-2422
FAQ
Who is the new Interim CEO of DSS, Inc. (NYSE American: DSS)?
What is Jason Grady's previous experience within DSS?
What are the main goals Jason Grady has set for DSS as Interim CEO?
Who did Jason Grady replace as CEO of DSS, Inc.?
